Iovance Biotherapeutics, Inc. IOVA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating income?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating income of -$81.04M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating income changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating income increased by 33.1% year-over-year, from -$121.22M to -$81.04M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s operating income has grown at a 4.2% compound annual growth rate (CAGR), from -$342.7M to -$403.36M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.